The present invention provides highly selective dual reuptake inhibitors of serotonin and norepinephrine. These compounds have a low side effect profile and are suitable for use in compositions and products for the treatment of various conditions including: depression, muscle fiber pain, anxiety, panic disorder, agoraphobia, post-traumatic stress disorder, Anxiety Disorder, Attention Deficit Disorder, Obsessive Compulsive Disorder, Social Anxiety Disorder, Generalized Anxiety Disorder, Autism, Schizophrenia, Obesity, Anorexia Nervosa, Bulimia, Gilles de la Tourette Syndrome , vasodilation flushing, cocaine and alcohol addiction, sexual dysfunction, borderline personality disorder, fibromyalgia syndrome, diabetic neuralgia, chronic fatigue syndrome, pain, visceral pain, Shy Drager syndrome syndrome), Raynaud's syndrome, Parkinson's Disease and epilepsy.